IN2012DN05143A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05143A
IN2012DN05143A IN5143DEN2012A IN2012DN05143A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A IN 5143DEN2012 A IN5143DEN2012 A IN 5143DEN2012A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A
Authority
IN
India
Prior art keywords
present
glioma
tbs40
nfl
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Joel Eyer
Alan Peterson
Julien Balzeau
Raphael Berges
Original Assignee
Univ Angers
Inst Nat Sante Rech Med
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Inst Nat Sante Rech Med, Univ Mcgill filed Critical Univ Angers
Publication of IN2012DN05143A publication Critical patent/IN2012DN05143A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN5143DEN2012 2009-12-14 2010-12-14 IN2012DN05143A (th)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (en) 2009-12-14 2009-12-14 Use of a neurofilament peptide for the treatment of glioma
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (1)

Publication Number Publication Date
IN2012DN05143A true IN2012DN05143A (th) 2015-10-23

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5143DEN2012 IN2012DN05143A (th) 2009-12-14 2010-12-14

Country Status (7)

Country Link
US (2) US9446092B2 (th)
EP (2) EP2332560A1 (th)
JP (1) JP5806679B2 (th)
CN (1) CN102821777B (th)
CA (1) CA2784091C (th)
IN (1) IN2012DN05143A (th)
WO (1) WO2011073207A1 (th)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP2959913A1 (en) * 2014-06-23 2015-12-30 Universite D'angers Use of a neurofilament peptide for targeting neural stem cells
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN108490191B (zh) * 2018-03-13 2019-04-16 首都医科大学附属北京地坛医院 神经丝蛋白轻链在梅毒血液检测中的应用
CN113195005B (zh) * 2018-10-12 2023-07-21 国际先进加速器应用公司 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4593865A1 (en) * 2022-09-30 2025-08-06 Gliocure Pharmaceutical composition comprising nfl-tbs40-63peptide, variants or salts thereof and alanine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire

Also Published As

Publication number Publication date
CN102821777B (zh) 2014-12-17
EP2512499A1 (en) 2012-10-24
CA2784091C (en) 2020-08-11
US20130004429A1 (en) 2013-01-03
CA2784091A1 (en) 2011-06-23
JP2013513646A (ja) 2013-04-22
JP5806679B2 (ja) 2015-11-10
US9446092B2 (en) 2016-09-20
CN102821777A (zh) 2012-12-12
EP2332560A1 (en) 2011-06-15
EP2512499B1 (en) 2015-09-16
US20170000846A1 (en) 2017-01-05
WO2011073207A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
IN2012DN05143A (th)
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MY184882A (en) Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
MX2009008096A (es) Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
NO20076401L (no) Diarylhydantoinforbindelser
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MY148299A (en) Iron-carbohydrate complex compounds
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
MX2010006039A (es) Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica.
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
MX2020012900A (es) Potentes inhibidores de d-aminoacido oxidasa (daao) y sus usos.